Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign
December 2020
in “Journal of The American Academy of Dermatology”
TLDR AGA linked to worse COVID-19 outcomes in men.
This document discusses the correlation between androgenetic alopecia (AGA) and COVID-19 outcomes. Several studies have found that AGA is more prevalent in COVID-19 patients than in the general population, and that the presence of the Gabrin sign (a skin manifestation of COVID-19) is associated with a higher prevalence of AGA. The severity of AGA, as measured by the Hamilton-Norwood scale, is also associated with worse outcomes in hospitalized men. The document suggests that AGA may be a risk factor for severe COVID-19 outcomes in men, and encourages further research on the topic.
View this study on jaad.org →
Cited in this study
research Androgenetic alopecia in COVID-19: Compared to what?
Hair loss link to severe COVID-19 unclear.
research Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”
Most COVID-19 patients in hospitals have androgenetic alopecia, more in men, suggesting a link between androgen sensitivity and severe COVID-19 symptoms.
research Androgen sensitivity gateway to COVID ‐19 disease severity
Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.
research Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors
Hair loss increases with age; alcohol raises risk, more female partners lowers it.